• Androgen-related symptoms: low libido, erectile dysfunction or reduced testosterone levels.
• Changes in body composition: loss of muscle mass, reduced strength or weight gain.
• Metabolic syndrome: concerns involving central adiposity or metabolic changes.
• Lipid profile changes: adverse shifts in cholesterol markers.
• Mood concerns: depression, irritability or reduced resilience.
• Sleep disturbance: difficulty falling asleep or waking through the night.
• Bone health concerns: osteoporosis or reduced bone density.
• Thyroid-related symptoms: low energy, temperature sensitivity or reduced stamina.
• Prostate monitoring: PSA evaluation within a broader hormonal context.
• Hypogonadism: reduced testosterone production or related symptoms.

Comprehensive Male I measures a combination of sex hormones, adrenal markers and thyroid analytes using saliva and bloodspot samples. Saliva is used to assess oestradiol, testosterone, DHEA-S and four-point cortisol, while bloodspot analysis provides PSA, TSH, free T3, free T4 and TPO antibodies. Together, these markers offer a broad perspective on interconnected hormonal systems.

This assessment may relate to concerns such as low libido, erectile dysfunction, fatigue, mood changes, weight gain, loss of muscle mass, sleep disturbance, adverse lipid patterns, osteoporosis, thyroid-related symptoms or the monitoring of PSA within a wider hormone profile. It may also be useful when evaluating patterns associated with ageing or suspected hypogonadism.

Practitioners typically interpret findings from Comprehensive Male I alongside symptom history, lifestyle factors, dietary intake, stress exposure, physical activity and information shared by clients. This helps develop a clearer understanding of how sex hormones, adrenal output and thyroid activity may align with reported experiences.

Practical

Specimen requirements:

Saliva + Dried bloodspot (DBS)

Average processing time:

14 ±6 days

Research

• Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM,McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-6.

• Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007;102:899-911.

• Elmlinger MW, Dengler T, Weinstock C, Kuehnel W. Endocrine alterations in the aging male. Clin Chem Lab Med. 2003;41:934-41.

• Endogenous Hormones, Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-83.

• Magri F, Cravello L, Barili L, Sarra S, Cinchetti W, Salmoiraghi F, Micale G, Ferrari E. Stress and dementia: the role of the hypothalamic-pituitary-adrenal axis. Aging Clin Exp Res. 2006;18(2):167-70.

• Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-9.

• Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. Oestrogens and prostate cancer. Endocr Relat Cancer. 2003;10:187-91.

• Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol. 2007;39:183-8.

• Selby C. Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem. 1990;27:532-41.

• Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alphareductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179:1235-42.